Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Post-Traumatic Stress Disorder (PTSD) Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Post-Traumatic Stress Disorder (PTSD) Overview | 11 | 1 |
| Pipeline Products for Post-Traumatic Stress Disorder (PTSD) Comparative Analysis | 12 | 1 |
| Post-Traumatic Stress Disorder (PTSD) Therapeutics under Development by Companies | 13 | 2 |
| Post-Traumatic Stress Disorder (PTSD) Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Post-Traumatic Stress Disorder (PTSD) Pipeline Products Glance | 16 | 4 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Unknown Stage Products | 19 | 1 |
| Post-Traumatic Stress Disorder (PTSD) Products under Development by Companies | 20 | 2 |
| Post-Traumatic Stress Disorder (PTSD) Products under Investigation by Universities/Institutes | 22 | 1 |
| Post-Traumatic Stress Disorder (PTSD) Companies Involved in Therapeutics Development | 23 | 20 |
| Addex Therapeutics Ltd | 23 | 1 |
| Amorsa Therapeutics Inc. | 24 | 1 |
| Azevan Pharmaceuticals, Inc. | 25 | 1 |
| Bionomics Limited | 26 | 1 |
| Catalyst Pharmaceuticals, Inc. | 27 | 1 |
| Eli Lilly and Company | 28 | 1 |
| Humanetics Corporation | 29 | 1 |
| Intra-Cellular Therapies, Inc. | 30 | 1 |
| INVENT Pharmaceuticals, Inc. | 31 | 1 |
| Marinus Pharmaceuticals, Inc. | 32 | 1 |
| Neuralstem, Inc. | 33 | 1 |
| NeuroNascent, Inc. | 34 | 1 |
| Omeros Corporation | 35 | 1 |
| Otsuka Holdings Co., Ltd. | 36 | 1 |
| Polleo Pharma Limited | 37 | 1 |
| Pragma Therapeutics | 38 | 1 |
| Synchroneuron Inc. | 39 | 1 |
| Tonix Pharmaceuticals Holding Corp. | 40 | 1 |
| TRImaran Pharma, Inc. | 41 | 1 |
| Turing Pharmaceuticals AG | 42 | 1 |
| Post-Traumatic Stress Disorder (PTSD) Therapeutics Assessment | 43 | 11 |
| Assessment by Monotherapy Products | 43 | 1 |
| Assessment by Target | 44 | 3 |
| Assessment by Mechanism of Action | 47 | 3 |
| Assessment by Route of Administration | 50 | 2 |
| Assessment by Molecule Type | 52 | 2 |
| Drug Profiles | 54 | 68 |
| acamprosate calcium SR Drug Profile | 54 | 2 |
| ADX-71743 Drug Profile | 56 | 1 |
| AM-3506 Drug Profile | 57 | 1 |
| BNC-210 Drug Profile | 58 | 3 |
| brexpiprazole Drug Profile | 61 | 6 |
| CPP-115 Drug Profile | 67 | 4 |
| D-473 Drug Profile | 71 | 1 |
| ganaxolone Drug Profile | 72 | 5 |
| HL-9001 Drug Profile | 77 | 1 |
| IC-87201 Drug Profile | 78 | 1 |
| INV-107 Drug Profile | 79 | 1 |
| INV-170 Drug Profile | 80 | 1 |
| ITI-007 Drug Profile | 81 | 8 |
| KDAC-0001 Drug Profile | 89 | 1 |
| ketamine hydrochloride Drug Profile | 90 | 1 |
| modafinil Drug Profile | 91 | 1 |
| NNI-351 Drug Profile | 92 | 1 |
| NSI-189 Drug Profile | 93 | 4 |
| PGT-117 Drug Profile | 97 | 1 |
| Rycal Drug Profile | 98 | 1 |
| S-107 Drug Profile | 99 | 1 |
| Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders Drug Profile | 100 | 1 |
| Small Molecule to Target GPR151 for CNS Diseases Drug Profile | 101 | 1 |
| Small Molecule to Target GPR83 for CNS and Immunological Disorders Drug Profile | 102 | 1 |
| Small Molecules for Post-Traumatic Stress Disorder Drug Profile | 103 | 1 |
| Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders Drug Profile | 104 | 1 |
| Small Molecules to Antagonize TLR-4 for CNS Disorders Drug Profile | 105 | 1 |
| Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder Drug Profile | 106 | 1 |
| SRX-246 Drug Profile | 107 | 2 |
| Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder Drug Profile | 109 | 1 |
| TNX-102 Drug Profile | 110 | 9 |
| URB-694 Drug Profile | 119 | 1 |
| Vaccine for CNS Disorders Drug Profile | 120 | 1 |
| ZL-006 Drug Profile | 121 | 1 |
| Post-Traumatic Stress Disorder (PTSD) Dormant Projects | 122 | 2 |
| Post-Traumatic Stress Disorder (PTSD) Discontinued Products | 124 | 1 |
| Post-Traumatic Stress Disorder (PTSD) Product Development Milestones | 125 | 11 |
| Featured News &Press Releases | 125 | 1 |
| Jun 30, 2016: Bionomics To Trial Drug Against Post-Traumatic Stress Disorder | 125 | 1 |
| Jun 13, 2016: Addex mGluR7 Program Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases | 125 | 1 |
| Jun 03, 2016: Tonix Pharmaceuticals to Present at the 2016 BIO International Convention | 126 | 1 |
| May 31, 2016: Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the American Society of Clinical Psychopharmacology 2016 Annual Meeting | 126 | 1 |
| May 26, 2016: Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting | 127 | 1 |
| May 19, 2016: Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD) | 128 | 1 |
| Mar 09, 2016: Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting | 129 | 1 |
| Dec 23, 2015: Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder | 130 | 1 |
| Dec 08, 2015: Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC210 | 130 | 1 |
| Nov 23, 2015: The SEVEN4PTSD consortium led by PRAGMA Therapeutics awarded 2015 French ANR grant to further advance its mGlu7 program for Post-Traumatic Stress Disorder | 131 | 1 |
| Oct 29, 2015: Marinus Announces Clinical Development Plans for Ganaxolone Intravenous Formulation | 132 | 1 |
| Aug 18, 2015: Tonix Pharmaceuticals Presents on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2015 Military Health System Research Symposium | 133 | 1 |
| May 26, 2015: Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR | 134 | 1 |
| May 15, 2015: Tonix Pharmaceuticals Presents Data at the Annual Meeting of the Society for Biological Psychiatry | 134 | 1 |
| Jan 15, 2015: Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder | 134 | 2 |
| Appendix | 136 | 2 |
| Methodology | 136 | 1 |
| Coverage | 136 | 1 |
| Secondary Research | 136 | 1 |
| Primary Research | 136 | 1 |
| Expert Panel Validation | 136 | 1 |
| Contact Us | 136 | 1 |
| Disclaimer | 137 | 1 |